-
After 12 years, Mengke Pharmaceutical announced that Contizolamide Tablets, a new anti-drug-resistant bacteria drug, was approved for marketing
Time of Update: 2021-06-11
Mengke Pharmaceutical is about to launch an international multi-center phase III clinical trial to support the approval of Contizolamide in other countries and/or regions such as Europe and the United States.
-
AstraZeneca launches next-generation PARP inhibitors to continue Lynparza's success
Time of Update: 2021-04-18
AstraZeneca hopes that AZD5305 will be a successful follow-up product to Lynparza and provide a wider range of combination treatment options and earlier treatments because of its higher specificity and the potential to reduce safety risks.
-
Orphan Drug Weekly | Selective IL-2 agonists and other 4 research therapies are shortlisted
Time of Update: 2021-03-21
Drug: Nemvaleukin alfaR&D company: AlkermesTreatment of disease: mucosal melanoma (mucosal melanoma)Introduction: Nemvaleukin alfa is an innovative engineering fusion protein under research, which is composed of modified interleukin-2 (IL-2) and a high-affinity IL-2α receptor chain, designed to selectively amplify tumor-killing effects Immune cells, while avoiding activating immunosuppressive cells.
-
Gilead, Kite and oNKo-innate have teamed up
Time of Update: 2021-02-28
yesterday, Gilead Sciences and its Kite company, oNKo-innate, jointly announced that they had agreed to a three-year research collaboration on cancer immunotherapy to discover and develop the next generation of natural killer cells (NK) therapies.
Current cancer immunotherapy methods focus on the anti-tumor immune response that activates T-cell-mediated.
-
Concorde Kirin pioneered the clinical success of ox40-targeted single-anti-KHK4083 Phase II
Time of Update: 2021-02-23
Japanese pharmaceutical company Kyowa Kirin recently announced that phase 2 studies evaluating the antibody drug KHK4083 for moderate to severe specific dermatitis (AD) adult patients have reached the main endpoint.
-
Cell Death Differ:PIWIL2 regulates the occurrence of autophagy and apoptosis of esophageal squamous cell cancer cells by interacting with IKK
Time of Update: 2021-02-01
As one of the most common malignant tumors in China, ESCC has a low five-year survival rate, which is also associated with the late diagnosis of the disease, frequent metastasis and the development of therapeutic resistance.
-
Clin Cancer Res: The activity of the trisexual T-cell activation protein HPN536 in malignant tumors that express mesothionin
Time of Update: 2021-01-25
HPN536 can effectively inhibit tumor growth experimental results confirmed that HPN536 can be combined with tumor cells expressing MSLN, and with the surface of T cells CD3, resulting in T cell activity and effective redirect target cell dissolution.
-
Sales of the top 10 new drugs approved by the FDA are expected to peak at $16 billion in 2020
Time of Update: 2021-01-19
2020 is a special year for drug regulatory approval. In part because the ongoing COVID-19 pandemic has delayed many clinical trials, but also because some highly anticipated drug applications have bee
-
BRAIN: Carcinogenic effects of SRSF3
Time of Update: 2021-01-16
it is worth noting that SRSF3 is directly related to the occurrence, development, aggression and patient survival of glioblastoma and represents a new potential therapeutic target for addressing this devastating pathology.
-
Blood: The contribution of Vav1 mutations in the occurrence of mature T-cell tumors
Time of Update: 2020-10-13
total transcription group analysis (WTA) showed that p53-/-Vav1-TG mice had multiple Myc-related path-riches in TCN compared to p53-/- or wild T-cells.
, JQ1, a bromine domain inhibitor targeted by the Myc path, treated naked mice transplanted with p53-/-Vav1-TG tumor cells, extending the survival time of mice.
-
The FDA has awarded IVT-8086 the title of Treating Rare Pediatric Disease (RPD) of Osteosarcoma
Time of Update: 2020-10-12
biopharmaceutical company Innova Therapeutics announced today that the FDA has awarded IVT-8086 the title of Rare Pediatric Disease (RPD) for the treatment of osteosarcoma (OS).
IVT-8086 is likely to be the first FDA-approved new treatment for osteosarcoma." .
-
Cell Rep: Multi-group studies reveal the detailed characteristics and heterogeneity of HIV-1 infected cells
Time of Update: 2020-09-12
August 6, 2020 // -- In order to eliminate HIV infection, it is important to clarify the detailed characteristics and heterogeneity of HIV-1 infected cells in the body, a recent study published in the international journal Cell Reports, scientists from the University of Tokyo and other institutions said that the use of genetically modified HIV-1 to infect human-based mouse models of hematopoietic stem cell transplants or hopefully reveal in the body the characteristics of cells producing HIV-1.
-
Seize the metabolic weakness of cancer! Real-time metabolic tracking and fat-free diet Tumor diagnosis and treatment effect is good
Time of Update: 2020-07-29
The study was carried out by the team of the iKnife Smart Knife inventor, Zoltan Takats of Imperial College London, and George Poulogiannis, and the findings were published in the journal Cell five y
-
Several immunotherapy failures of the urinary road skin cancer ushered in a new pattern of first-line maintenance treatment
Time of Update: 2020-07-24
Vencoon pie urine path skin cancer (UC) originated from transcutaneous, the vast majority of which originated from the bladder (about 90%), for the initial treatment of metastatic urinary skin cancer
-
Prostate male patients with prostate prostate in the prostate of atovastatin entry pathways and concentrations
Time of Update: 2020-07-16
Statins have anti-cancer effects on prostate cancer both in and around the body !---- it is not clear whether this is due to systemic cholesterol reduction or direct inhibition of local prostate grow
